Wall Street Zen Upgrades Collegium Pharmaceutical (NASDAQ:COLL) to Buy

Key Points

• Wall Street Zen upgraded Collegium Pharmaceutical from “hold” to “buy.” Analyst views remain mixed, but MarketBeat reports a “Moderate Buy” consensus and an average price target of $44.88; Piper Sandler cut its target from $43 to $28 and kept a neutral rating.
• Collegium reported quarterly EPS of $1.96, beating the $1.86 consensus, and revenue of $216.34 million, slightly above expectations and up 67.4% year over year. EPS was below the $2.25 recorded in the year-earlier quarter.
• Shares opened at $24.21 after a reported 3.8% decline, well below the stock’s one-year high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a note issued to investors on Saturday, Wall Street Zen reports.

A number of other equities research analysts have also weighed in on the stock. Leerink Partners assumed coverage on shares of Collegium Pharmaceutical in a report on Wednesday, September 9th. They set an "outperform" rating and a $45.00 price objective on the stock. Barclays cut their target price on Collegium Pharmaceutical from $56.00 to $48.00 and set an "overweight" rating for the company in a research report on Wednesday, August 19th. Weiss Ratings lowered Collegium Pharmaceutical from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Friday, September 4th. Piper Sandler dropped their price target on Collegium Pharmaceutical from $43.00 to $28.00 and set a "neutral" rating for the company in a research note on Friday. Finally, Jefferies Financial Group reaffirmed a "buy" rating and set a $35.00 target price on shares of Collegium Pharmaceutical in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $44.88.

Collegium Pharmaceutical Stock Down 3.8%

Shares of COLL opened at $24.21 on Friday. Collegium Pharmaceutical has a one year low of $21.43 and a one year high of $50.79. The company has a debt-to-equity ratio of 3.32, a current ratio of 1.03 and a quick ratio of 0.84. The company has a market cap of $788.28 million, a P/E ratio of 3.39, a P/E/G ratio of 0.74 and a beta of 0.75. The firm has a 50 day simple moving average of $22.99 and a two-hundred day simple moving average of $32.79.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The specialty pharmaceutical company reported $1.96 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.86 by $0.10. The firm had revenue of $216.34 million during the quarter, compared to the consensus estimate of $216.03 million. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%. The business's revenue for the quarter was up 67.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.25 EPS. Research analysts forecast that Collegium Pharmaceutical will post 6.42 EPS for the current fiscal year.

Institutional Investors Weigh In On Collegium Pharmaceutical

Institutional investors have recently bought and sold shares of the stock. BlackRock Inc. purchased a new stake in shares of Collegium Pharmaceutical during the second quarter valued at $196,972,000. Jupiter Topco LLC purchased a new stake in Collegium Pharmaceutical during the second quarter worth about $77,743,000. Janus Henderson Group PLC grew its position in Collegium Pharmaceutical by 26.0% in the first quarter. Janus Henderson Group PLC now owns 1,825,651 shares of the specialty pharmaceutical company's stock valued at $60,358,000 after acquiring an additional 377,073 shares in the last quarter. Bank of America Corp DE acquired a new stake in Collegium Pharmaceutical in the second quarter worth approximately $9,882,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Collegium Pharmaceutical in the second quarter worth about $8,506,000.

Collegium Pharmaceutical News Summary

Here are the key news stories impacting Collegium Pharmaceutical this week:

• Positive Sentiment: Q3 adjusted earnings of $1.96 per share topped consensus estimates, and revenue of $216.3 million narrowly beat expectations. The company reported record quarterly revenue, including JORNAY PM revenue up 24% year over year. Collegium Q3 2026 results
• Positive Sentiment: FY 2026 revenue guidance is $825 million–$855 million, a range whose midpoint is above the $832.9 million consensus estimate. Collegium also announced a $50 million accelerated share repurchase. Collegium Q3 2026 results
• Neutral Sentiment: Needham lowered its price target from $46 to $44 but maintained a Buy rating, indicating continued optimism alongside a more cautious valuation. Needham lowers Collegium price target
• Negative Sentiment: Piper Sandler cut its target sharply, from $43 to $28, and assigned a Neutral rating. The lower valuation outlook could weigh on sentiment despite the target remaining above the referenced share price. Piper Sandler rating
• Negative Sentiment: EPS declined from $2.25 in the year-ago quarter to $1.96, tempering the earnings beat. Collegium Q3 earnings

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for pain management and central nervous system disorders. The company primarily serves the U.S. market and emphasizes products designed to address significant patient and healthcare-provider needs.

Its pain portfolio includes Xtampza ER, an extended-release oxycodone formulation designed with abuse-deterrent properties, as well as Nucynta and Nucynta ER, which contain tapentadol and are used to treat acute and chronic pain.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.